Financials data is unavailable for this security.
View more
Year on year Strides Pharma Science Ltd grew revenues 9.83% from 36.88bn to 40.51bn. Additionally the company has reduced the cost of goods sold, selling, general and administrative expenses and debt expenses (all as percentages of sales). These changes narrowed profitability losses from -2.03bn to -706.14m.
| Gross margin | 60.19% |
|---|---|
| Net profit margin | 3.91% |
| Operating margin | 14.53% |
| Return on assets | 2.79% |
|---|---|
| Return on equity | 8.19% |
| Return on investment | 5.43% |
More ▼
Cash flow in INRView more
In 2024, cash reserves at Strides Pharma Science Ltd fell by 1.42bn. However, the company earned 7.01bn from its operations for a Cash Flow Margin of 17.30%. In addition the company used 1.50bn on investing activities and also paid 6.93bn in financing cash flows.
| Cash flow per share | 40.44 |
|---|---|
| Price/Cash flow per share | 37.20 |
| Book value per share | 247.16 |
|---|---|
| Tangible book value per share | 124.08 |
More ▼
Balance sheet in INRView more
| Current ratio | 1.04 |
|---|---|
| Quick ratio | 0.6355 |
| Total debt/total equity | 1.02 |
|---|---|
| Total debt/total capital | 0.5103 |
More ▼
Growth rates in INR
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 66.67% and 44.14%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally, five year annualized dividend per share growth ranks below the industry average relative to its peers.
| Div yield(5 year avg) | 0.79% |
|---|---|
| Div growth rate (5 year) | -3.58% |
| Payout ratio (TTM) | 12.98% |
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 176.13 |
More ▼
